Page 1 2 ... 30 40 50 ... 200 ... NEXT>>
[ October 31, 2014 | Author: admin | Views: 47971 | Weather: | Mood: normal]

European stocks closed little changed, as the benchmark Stoxx Europe 600 Index extended its highest level since June 2008. Snam SpA (SRG) dropped the most in almost a year as Eni SpA sold an 11.7 percent stake in the owner of Italys biggest natural-gas network. Wm Morrison Supermarkets Plc tumbled the most in more than 14 months. Experian Plc jumped to a record after the worlds largest credit-checking company raised its dividend and announced a share buyback. The Stoxx 600 added less than 0.1 percent to 303.74 at the close in London. The benchmark gauge advanced yesterday amid better-than-estimated corporate earnings and has gained 8.6 percent so far in 2013, its best start to a year since 2006. Markets in Switzerland, the Nordic countries and Austria are closed today for Ascension Day. Most businesses closed today in Germany for the holiday. After stock markets roared back recently, market participants are … Continue reading

[ October 31, 2014 | Author: admin | Views: 48637 | Weather: | Mood: normal]

Small cap money transfer stock Euronet Worldwide, Inc (NASDAQ: EEFT) and Wal-Mart Stores, Inc (NYSE: WMT) have announced an exclusive money transfer service called “Walmart-2-Walmart, meaning its time to take a closer look at the stock along with the performance of peers like Moneygram International Inc (NASDAQ: MGI), Xoom Corp (NASDAQ: XOOM) and The Western Union Company (NYSE: WU) which fell 17.68%, 4.32% and 4.98%, respectively. What is Euronet Worldwide, Inc? Founded in 1994, small cap Euronet Worldwide is a global provider of electronic payment and transaction processing solutions for financial institutions, retailers, service providers and individual consumers.Euronet Worldwides three primary business segments (EFT, epay and Ria Money Transfer) are supported by 4,100 employees in 39 countries while last year, the company processed 2.3 billion transactions and posted annual revenues of approximately $1.4 billion. In addition, the company is operating the largest independent nationwide shared ATM network in India andthe … Continue reading

[ October 31, 2014 | Author: admin | Views: 52369 | Weather: | Mood: normal]

Pension funds and other institutional investors have struggled to produce the returns they need to satisfy their obligations. To boost returns, they’ve turned to a new, risky strategy involving leverage that could eventually backfire, leaving pension funds facing shortfalls in meeting their obligations to pensioners. In the following video, Fool markets analyst Mike Klesta talks with longtime Fool contributor and financial planner Dan Caplinger about this strategy and what it means to you and your money. Annaly Capital has used a similarly leveraged strategy to produce huge dividends, but can investors count on that payout sticking around? With the Federal Reserve’s recent moves, Annaly has had to scramble to defend its bottom line. In The Motley Fool’s premium research report on Annaly, senior analysts Ilan Moscovitz and Matt Koppenheffer uncover the key challenges the company faces and divulge three reasons investors may consider buying it. Simply click here now to … Continue reading

[ October 31, 2014 | Author: admin | Views: 50828 | Weather: | Mood: normal]

DELAFIELD, Wis. (Stockpickr) — The recent selloff in the biotechnology complex is creating golden opportunities throughout the sector for potential rebound plays. Some of these plays have massive upside potential, with huge short interest and beaten-down charts. The sentiment on some of these stocks is extremely negative. Many of these biotech stocks also have upcoming catalyst events that could be a major driver for higher share prices. From my viewpoint, now is the time to start digging into these beaten-down names — especially in the small-cap segment of the biotechnology world. >>3 Biotech Stocks Rising on Unusual Volume One speculative biotechnology stock that’s catching my eye here is CytRx (CYTR), which operates as a biopharmaceutical research and development company specializing in oncology. This company’s oncology pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx is … Continue reading

[ October 31, 2014 | Author: admin | Views: 6045 | Weather: | Mood: normal]

There’s no foolproof way to know the future for Healthcare Services Group (Nasdaq: HCSG  ) or any other company. However, certain clues may help you see potential stumbles before they happen — and before your stock craters as a result. A cloudy crystal ball In this series, we use accounts receivable and days sales outstanding to judge a company’s current health and future prospects. It’s an important step in separating the pretenders from the market’s best stocks. Alone, AR — the amount of money owed the company — and DSO — the number of days’ worth of sales owed to the company — don’t tell you much. However, by considering the trends in AR and DSO, you can sometimes get a window onto the future. Sometimes, problems with AR or DSO simply indicate a change in the business (like an acquisition), or lax collections. However, AR that grows more quickly than … Continue reading